MorphoSys in a nutshell

Dr. Jean-Paul Kress joined MorphoSys in September 2019. He has a strong track record of commercial and (operational) strategic leadership in various senior management roles in North America and Europe. His focus has been on operations, corporate development and especially the commercialization of innovative products addressing unmet medical needs across diverse disease indications. Prior to joining MorphoSys, Dr. Kress served as President and Chief Executive Officer at Syntimmune, a clinical-stage biotechnology company developing differentiated drug candidates in a wide range of autoimmune diseases, which was acquired by Alexion in November 2018. Among other assignments, he was Executive Vice President, President of International and Head of Global Therapeutic Operations at Biogen, and Senior Vice President, Head of North America at Sanofi Genzyme, where he was instrumental in launching Dupilumab, the first biologic agent approved in atopic dermatitis. Previously, he was President and Chief Executive Officer of Sanofi Pasteur MSD, and gained further experience in positions at Gilead, Abbvie and Eli Lilly. 

Dr. Kress received an M.D. degree from Faculté Necker-Enfants Malades in Paris, and graduate and post-graduate degrees in biochemistry and in molecular and cellular pharmacology from Ecole Normale Supérieure in Paris.
 

MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES

Sung Lee came to MorphoSys in February 2021 and leads all corporate finance functions of the company.

Sung Lee has more than 20 years of finance leadership experience in biopharmaceutical and technology businesses. He joined MorphoSys from Sangamo Therapeutics, Inc., where he served as Chief Financial Officer. Prior to that role, Mr. Lee spent nearly 14 years at Gilead Sciences where he most recently led the global Financial Planning & Analysis and Investor Relations functions.

Lee started his career in the tax advisory business at PriceWaterhouseCoopers LLP. He received a Master of Business Taxation from the University of Southern California and a B.A. in Economics from the University of California, Irvine.

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

None

Charlotte Lohmann joined MorphoSys in May 2012. She is a very experienced lawyer with more than 20 years of professional practice, having worked in both top tier international audit and law firms as well as in publicly listed biotech companies. 
She is an accomplished executive that has established solution-oriented legal departments with a focus on performance, effectiveness and making the legal department a true business partner. She has been successful in setting up and executing international projects as well as public listings on Frankfurt Stock Exchange and Nasdaq and has vast experience in advising management and supervisory boards (both as General Counsel and supervisory board member). 
Prior to joining MorphoSys she worked for Wilex AG as Sr. VP Legal Affairs & Human Resources and for KPMG as Corporate Lawyer.
Charlotte Lohmann holds a Law Degree from the University of Munich and is an accredited lawyer in Germany. 

Dr. Peters joined MorphoSys from Sandoz International, Holzkirchen, Germany, where he was Global Head of Clinical Development of the Biopharmaceuticals Business Unit. Prior to this position, he served as Clinical Head and Site Head for Basel and East Hanover in the department of Oncology Translational Medicine at Novartis. Dr. Peters held teaching appointments in Internal Medicine and Biochemistry at the University of Mainz, Germany.

Dr. Peters received his MD degree from the Freie Universität Berlin, Germany, and was trained at the Universities of Padova, Italy and Bochum and Berlin, Germany. After scientific work at different universities he received his habilitation in Internal Medicine at the University of Mainz, Germany. Subsequently, he served as Research Scientist at the Amgen Research Institute in Toronto, Canada, as Director of Cancer Research at Merck KgaA in Darmstadt, Germany and as Medical Director at Micromet AG in Munich, Germany.

Memberships in statutory supervisory boards and/or in comparable domestic or foreign supervisory bodies of commercial enterprises

Dr. Barbara Krebs-Pohl is a highly regarded business development executive with an outstanding track record of accomplishment of revenues and forging successful alliances with pharma and biotechnology companies worldwide. 

Since joining MorphoSys in 1998, Dr. Krebs-Pohl has successfully led R&D teams, international alliances and negotiation teams spanning a broad variety of deal structures. She has been instrumental in program search & evaluation, portfolio strategy and a multitude of transactions, including the in-licensing of tafasitamab from Xencor, the long-term HuCAL alliance with Novartis and the co-development and co-commercialization partnership with Incyte. She is also the winner of the "Astra Zeneca Business Development Executive of the Year 2013" Award.

Prior to joining MorphoSys, Dr. Krebs-Pohl earned the opportunity to work with Nobel Prize winner Sir Greg Winter at MRC/LMB Cambridge, UK. She holds a PhD from the University of Mainz in Immunology, theoretical Physics and Biochemistry. She is a Master of Science (MSc) Chemistry from the University of Cologne and further trained at the RWTH Aachen University with focus on Medical Biology and Bacteriology.

Dr. Roland Wandeler joined MorphoSys in May 2020. He has more than 15 years of commercial leadership and general management experience in the pharmaceutical and biotechnology industry, with a strong track record of building and leading sizable affiliates and U.S. franchises across multiple therapeutic areas, including oncology and hematology. Prior to MorphoSys, Dr. Wandeler held positions of increasing responsibility at Amgen, Inc., including General Manager Germany in Munich and General Manager Spain & Portugal in Barcelona, before most recently serving as Corporate Vice President and General Manager of Amgen’s US Bone Health and Cardiology Business Unit in Thousand Oaks, California. Dr. Wandeler initially joined Amgen in 2006 in strategic planning for its international business. Subsequent highlights include sales and business unit leadership roles in Germany at the time of several launches across therapeutic areas. Dr. Wandeler began his career at Boston Consulting Group (BCG) in Zurich, Switzerland and Los Angeles, California, where he was a core member of BCG’s global Healthcare Practice as well as a Member of the Zurich and Los Angeles Management Teams.

Dr. Wandeler holds a M.Sc. in Chemical Engineering and a Doctorate in Technical Sciences from ETH Zurich.

MEMBERSHIPS IN STATUTORY SUPERVISORY BOARDS AND/OR IN COMPARABLE DOMESTIC OR FOREIGN SUPERVISORY BODIES OF COMMERCIAL ENTERPRISES

No other memberships.

Maria Castresana is a global HR Executive with extensive international experience in the pharmaceutical and chemical industry gained over more than 20 years of professional experience in Spain, Germany and the USA. 

Prior to joining MorphoSys in 2020, Maria Castresana held positions of increasing responsibility at Boehringer Ingelheim, a global pharmaceutical player that expanded in recent years into oncology and specialty.  She lately served as Global Head of Talent, Leadership & Organizational Effectiveness. Among other assignments, she was Global Business Partner for Consumer Health Care and led the carve-out and sale of the business in the frame of BI's and Sanofi's SWAP of CHC and Animal Health business, which closed on January 1st, 2017.  Furthermore, she spent several years in the USA and was instrumental in the set-up of new commercial launch teams for Oncology, Diabetes and Cardiovascular.

Previously, she also worked for Ecolab as European Compensation Manager and gained early experience at Bayer. 

Maria Castresana received a Law Degree and a Business Administration Degree from the University of Deusto in Spain and a Master in Human Resources from Rutgers University in the USA. 

Daniel Palmacci brings over 20 years of experience in the international pharmaceutical industry with responsibility for Manufacturing, Supply Chain and Operational Excellence, leading cross-functional teams responsible for Pharmaceutical cGMP Production of Biologics API and sterile Fill & Finish, Manufacturing Science & Technology and Launch Management of new biotech products and biosimilars.

Before joining MorphoSys he has been working in various senior roles at MSD and Novartis in Germany, Austria and Switzerland. He spent many years in the United States, where he was responsible for the construction of the new cGMP certified biopharmaceutical facility at Schering AG, Seattle. Later Daniel took over the responsibility for a biopharmaceutical manufacturing facility for BayerHealthCare in the United States. He has a wide multicultural experience through international assignments in Germany, Italy, India, Brazil and the US.

Daniel holds a master’s degree in Chemistry and Process Engineering from the University of Berlin.